evidence provides a latest Japanese randomized controlled
trial (RCT) indicating that if patients with serosa-negative
cancer, even at presence of lymph nodes metastases,
treated appropriately with a complete and effective
D2 node dissection, they have a very high probability
Given the moderate prognosis of the patients with
this tumor-specific tumor stage in the West, could
a Japanese-style treatment approach improve the clinical
outcomes of these patients in the USA and Europe?
How feasible is this treatment strategy and what are
the limitations for a wide clinical use in the West?
Research focus on innovative-agents development or
surgeon’s education on appropriate D2 dissection
is the most effective way of western public-health
care towards improvement of the outcomes of patients
with early-stage gastric cancer?